Literature DB >> 21794834

Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer.

Ghassan K Abou-Alfa, Leonard B Saltz.   

Abstract

Entities:  

Year:  2011        PMID： 21794834     DOI： 10.1053/j.gastro.2011.04.063

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  3 in total

1.  Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.

Authors:  Elena B Kostova; Boukje M Beuger; Thomas R L Klei; Pasi Halonen; Cor Lieftink; Roderick Beijersbergen; Timo K van den Berg; Robin van Bruggen
Journal:  Biosci Rep       Date:  2015-04-16       Impact factor: 3.840

2.  Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.

Authors:  John Wong; Logan B Smith; Eli A Magun; Thomas Engstrom; Kirsten Kelley-Howard; Dakshina M Jandhyala; Cheleste M Thorpe; Bruce E Magun; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

3.  The flip side of doxorubicin: Inflammatory and tumor promoting cytokines.

Authors:  Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.